Trial reportClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2010
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.
Trial report in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00911612 (A Phase IIB Study to Evaluate the Effects of Welchol), which is not on this map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIB Study to Evaluate the Effects of Welchol (Colesevelam Hydrochloride) on Colonic Transit, Intestinal Permeability and Bowel Function in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.Digestive diseases and sciences · 2013Pooled it
- Re-establishing bile acid composition after treatment of recurrentGut microbes · 2026Trial
- Effects of low-dose medium-chain triglycerides on bowel habit outcomes in Japanese adults prone to constipation: a randomized, double-blind, LCT-controlled crossover trial.Frontiers in nutrition · 2026Trial
- Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Trial
- Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes.EBioMedicine · 2020Trial
- A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome.The Journal of clinical investigation · 2020Trial
- The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes.Diabetes · 2013 · on this mapTrial
- Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function.Diabetes care · 2012Trial
- Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.Digestive diseases and sciences · 2012Trial
- A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.The American journal of gastroenterology · 2011Trial
- Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.Gastroenterology · 2010Trial
- Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications.Cureus · 2026Review
- Real-world management of SeHCAT-confirmed bile acid diarrhoea: response to colestyramine and predictors of treatment success.Gastroenterology report · 2026Article
- Understanding the therapeutic toolkit for inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- The role of the gut microbiome in disorders of gut-brain interaction.The FEBS journal · 2025Review
- Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.PloS one · 2025Article
- Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism.Cell proliferation · 2024Article
- Bile acids differentially regulate longitudinal smooth muscle contractility in everted mouse ileum.FASEB bioAdvances · 2024Article
- The function of the gut microbiota-bile acid-TGR5 axis in diarrhea-predominant irritable bowel syndrome.mSystems · 2024Article
- Evaluation of Alternative Treatment Strategies for Bile Acid Malabsorption in Inflammatory Bowel Disease Patients: A Network Meta-Analysis.Journal of clinical medicine research · 2024Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsDi-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), and bile acid binding have unclear effects on colonic transit in health and disease.
methodsWe performed 2 randomized, double-blind, placebo-controlled studies. In healthy volunteers (20 per group), we evaluated the effects of oral placebo, 500 mg, or 1000 mg of CDC (delayed-release, each given for 4 days) on gastrointestinal and colonic transit. A second trial compared the effects of colesevelam (1.875 g, twice daily) versus placebo in 24 patients (12 per group) with diarrhea-predominant irritable bowel syndrome (IBS-D) on transit, daily bowel frequency and consistency, and colonic mucosal permeability. Serum fasting 7alpha-hydroxy-4-cholesten-3-one (7alphaC4) was measured to screen for bile acid malabsorption. Effects of treatments on transit were compared using analysis of covariance with body mass index and 7alphaC4 as covariates.
resultsIn healthy volunteers, CDC significantly accelerated colonic transit (at 24 and 48 hours, P = .01 and P < .0001, respectively), increased stool frequency and ease of passage (both P < .001), and evacuation (P = .02), and decreased stool consistency (P < .001). Four of the 24 IBS-D patients had increased serum 7alphaC4 levels. In IBS-D, colesevelam modestly affected overall colonic transit (24 h; P = .22). Emptying of the ascending colon took an average of 4 hours longer in patients given colesevelam compared with placebo; treatment effect was associated with baseline serum 7alphaC4 levels (P = .0025). Colesevelam was associated with greater ease of stool passage (P = .048) and somewhat firmer stool consistency (P = .12). No effects on mucosal permeability or safety were identified.
conclusionsSodium chenodeoxycholate in health and colesevelam in IBS-D patients have opposite effects on colonic transit and fecal parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.